SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 61.97-3.2%Nov 3 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: software salesperson who wrote (52001)5/4/2023 4:49:59 PM
From: software salesperson2 Recommendations

Recommended By
DewDiligence_on_SI
Lance Bredvold

  Read Replies (2) of 52153
 
alzforum.org

pros and cons of donanemab, lecanemab, and aducanumab.

questions, courtesy of Erik Musiek , Washington University School of Medicine:

A few questions for the future come to mind:

Are there ways to limit severe ARIA risk with these drugs? Biomarkers? Changes to the dosing regimen?

Is lecanemab actually safer than donanemab? If so, might it be preferentially used in higher-risk patients?

Is the tau PET stratification scheme used in this trial feasible in clinical practice?

How will we detect when plaques re-accumulate, and what can we do then? If donanemab cannot be given again due to antibody responses, would a different agent be used? Is a maintenance dose needed? The details of long-term therapy are unclear.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News